1. Endogenous tumour necrosis factor-alpha sensitise melanoma cells to glucosaminylmuramyl dipeptide.
- Author
-
Valyakina TI, Komaleva RL, Petrova EE, Malakhov AA, Shamborant OG, Andronova TM, and Nesmeyanov VA
- Subjects
- Acetylmuramyl-Alanyl-Isoglutamine pharmacology, Animals, Antigens, Neoplasm biosynthesis, Antigens, Neoplasm drug effects, Cell-Free System physiology, Culture Media, Conditioned pharmacology, Flow Cytometry, Humans, Melanoma immunology, Mice, Tumor Cells, Cultured, Acetylmuramyl-Alanyl-Isoglutamine analogs & derivatives, Adjuvants, Immunologic pharmacology, Melanoma metabolism, Tumor Necrosis Factor-alpha physiology
- Abstract
Flow cytometry was used to demonstrate that cultured human melanoma BRO cells expressed membrane-bound tumour necrosis factor-alpha (TNF-alpha) and were able to release TNF-alpha upon treatment with glucosaminylmuramyl dipeptide (GMDP). The released TNF-alpha was shown to prime melanoma cells, previously unable to respond to GMDP by increasing expression of melanoma-associated antigens, making them sensitive to GMDP treatment.
- Published
- 1998
- Full Text
- View/download PDF